Telbivudine, an antiviral nucleoside analogue, is marketed for the treatment of chronic hepatitis B. It has no tangible clinical advantages over lamivudine, a drug to which it is closely related (1).Cases of arthraJgia and myalgia associated with elevated plasma creatine kinase activity were observed in pre-marketing studies (1). The European Medicines Agency received reports of 6 cases of rhab-domyolysis and 8 cases of lactic acidosis between March 2008 and August 2008 (2).
展开▼
